Yarrow Bioscience (NASDAQ:YARW) Stock Price & Analysis

–

USD

–(–)

Company Profile

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

CEORebecca Velez Frey

SectorHealthcare

IndustryBiotechnology

Employees10

IPO DateJul 28, 2026

ExchangeNASDAQ

Exchange NameNASDAQ

CurrencyUSD

Headquarters & Contact

Address470 James Street, Suite 007

City / State / ZIPNew Haven, CT, 06513

CountryUnited States

Websitehttps://www.yarrowbioscience.com

Yarrow Bioscience Inc

Company Profile

Recently from Cashu